Moneycontrol
Last Updated : May 16, 2018 01:30 PM IST | Source: Moneycontrol.com

Granules India gains 4% on Establishment Inspection Report from USFDA for Jeedimetla unit

Jeedimetla facility manufactures active pharmaceutical ingredients (APIs) and pharmaceutical formulation intermediates (PFIs).

Moneycontrol News @moneycontrolcom
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Granules India share price rallied more than 4 percent after the company received Establishment Inspection Report (EIR) from the US health regulator for facility in Telangana.

The US Food and Drug Administration inspected Jeedimetla facility (Hyderabad) in March 2018 and issued one 483 observation during the inspection.

The pharma company said it has responded to the observation within the stipulated timeframe.

Jeedimetla facility manufactures active pharmaceutical ingredients (APIs) and pharmaceutical formulation intermediates (PFIs).

At 13:22 hours IST, the stock price was quoting at Rs 97.55, up Rs 2.90, or 3.06 percent on the BSE.
First Published on May 16, 2018 01:30 pm
Loading...
Sections
Follow us on
Available On